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Both chronic stress (1) and anxiety
disorders (2) are risk factors for develop-
ing alcohol use disorders (AUDs). Con-
versely, chronic alcohol consumption can
increase anxiety via a rebound effect and
acute withdrawal symptoms, thus con-
tributing to anxiety-related development
of AUDs and their maintenance (3). As
such, there is a rationale and growing inter-
est in developing medications with anti-
stress and/or anxiolytic properties as puta-
tive treatments for AUDs. To this end, ani-
mal models that approximate or are rele-
vant to human conditions of chronic stress
and anxiety are relevant to test the effect of
potential medications on alcohol-seeking
behaviors.
Many rodent models of stress use
either conditioned responses (e.g., shocks
paired with stimuli) or unconditioned
responses (e. g., natural predators) to
provoke anxiety (4). Yet these models
are of limited relevance to the expe-
rience of chronic psychosocial stressors
and the resultant anxiety disorders seen
in humans. In the study discussed here,
Peters and colleagues (5) used a mouse
model of chronic psychosocial stress pre-
viously developed by the same group (6).
The model involves chronic subordinate
colony housing (CSC), where a mouse is
placed in the same cage with a socially
dominant mouse for 19 days. The corre-
sponding control condition is where the
mouse is in a single housing (SH) for
the same duration. Previous studies with
this model, using male mice only, reveal
that CSC effects increased anxiety behav-
ior as measured by elevated plus maze
and light-dark box (6, 7). Accompany-
ing this anxiety behavior is a reduction
body weight gain and thymus weight,
increased adrenal weight, and blunted cor-
tisol response to circadian stimulation
in vivo and adrenocorticotropic hormone
(ACTH) challenge in vitro. The dysreg-
ulation observed in biomarkers of stress
response perhaps explains the colonic
inflammatory response also observed in
this model (6). However, in vivo, cortisol
levels were elevated in CSC mice compared
to SH mice during 5 min exposure to an
elevated platform, indicating intact acute
stress response (8). Interestingly, exposure
to CSC differentially affects hypothala-
mic expression of vasopressin and oxy-
tocin in the paraventricular nucleus with
an increase in the former and no change in
the latter (7).
In the present study (5), the authors first
validated 14 (vs. the previously validated
19) days of CSC as a stress provocation.
Fourteen days of CSC resulted in increased
anxiety behavior, as measured by signifi-
cantly less time spent in the lit box com-
pared to SH mice. Second, they demon-
strated that this stressor led to increased
ethanol consumption and preference with-
out affecting the same for sweet or aversive
non-alcoholic substances, thus suggesting
an effect that is specific for alcohol-related
behaviors.
The authors also tested the effect of
two anxiolytic molecules, baclofen, and
oxytocin, on drinking behavior as a con-
sequence of CSC compared to SH. Both
baclofen and oxytocin have been proposed
as medications for AUDs. Intriguingly,
there is preliminary evidence that the
anxiolytic, anti-craving action of baclofen
might be mediated, perhaps, by an oxy-
tocinergic mechanism in the supraoptic
nucleus of the hypothalamus (9). However,
in this study the combination of baclofen
and oxytocin was not investigated, nor
the effects of baclofen on oxytocin lev-
els. Therefore, future studies are warranted
to address whether they share common
pathways of action.
In preclinical studies, baclofen decreases
chronic ethanol consumption in rodents
undergoing the alcohol-water “free choice”
paradigm (10, 11). Baclofen also reduces
lever presses for alcohol in mice and rats
(12–16). Perhaps most relevant to study
discussed here is that post-dependent rats
in a state of withdrawal (which is anxio-
genic) after given baclofen, show decreased
alcohol self-administration, anxiety behav-
iors, tremors, and seizures (10, 17–19).
A few human studies show addi-
tional promise of baclofen in reduc-
ing ethanol consumption and anxiety
symptoms. Two double-blind placebo-
control studies demonstrated that baclofen
is superior to placebo in preventing
relapse (20, 21) [but see (22) for con-
flicting results]. Decreased anxiety lev-
els and biomarkers of the stress response
in alcoholic participants are also seen
after administration of baclofen (20,
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23–25). Furthermore, consistent with
the preclinical literature, clinical studies
show that baclofen may be effective in
reducing alcohol withdrawal symptoms,
including withdrawal-related anxiety levels
(26, 27).
As for oxytocin, much of the animal
research investigating oxytocin within the
context of addiction have centered on its
ability to inhibit and reverse tolerance to
ethanol and morphine (28). Additionally,
oxytocin has been shown to decrease alco-
hol preference (29). In alcohol preferring
rats, a single administration oxytocin, i.p.
(1 mg/kg) prior to alcohol access, resulted
in significantly reduced preference for alco-
hol lasting 6 weeks (29). To our knowledge,
only one small pilot clinical trial in heavy
drinkers, has examined the effects of oxy-
tocin on alcohol withdrawal symptoms.
Compared with placebo, oxytocin signif-
icantly decreased withdrawal symptoms
and reduced the amount of lorazepam
administered “as needed” during detoxifi-
cation (30).
In the study by Peters and colleagues,
after establishing that 14 days of CSC
results in significantly increased anxiety
behavior and increased alcohol consump-
tion and preference, this rodent model
of stress and anxiety was used to test
the effect of baclofen and oxytocin on
subsequent drinking behavior. A single
dose each of systemic baclofen, oxytocin,
and vehicle as well as a single dose of
intracerebroventricular (i.c.v.) oxytocin or
vehicle was given following 2 weeks of a
two bottle free choice period of increas-
ing concentrations of ethanol up to 8%.
Ethanol consumption and preference were
the main outcome measures, with saccha-
rine and quinine as positive and nega-
tive controls, respectively. Baclofen signif-
icantly reduced alcohol consumption and
preference in both groups of mice. In
contrast, oxytocin reduced alcohol con-
sumption only with peripheral administra-
tion and only in the SH group. For both
drugs, there was a compensatory increase
in water consumption, with no signifi-
cant difference from baseline in total liquid
consumption.
A fundamental question, evaluating the
results of this study, is the effect of increased
alcohol consumption on the anxiogenic
phenotype in the CSC group. While the
CSC mice exhibit more anxiety behavior
and consume more alcohol, the experimen-
tal design did not allow for determination
of anxiety-like behavior as a consequence
of both CSC and alcohol consumption.
Therefore, one cannot say whether the
stress manipulation together with the
exposure to alcohol also resulted in an anx-
iogenic phenotype. This is important in
evaluating the observed effect of both drugs
on drinking behavior in the context of each
drug’s anxiolytic properties.
It is interesting that baclofen and oxy-
tocin have been shown to decrease alco-
hol consumption and/or decrease anxiety-
related alcohol withdrawal symptoms, both
in rodents (10, 28, 29) and in humans
(26, 27, 30, 31). However, in this CSC
model of anxiety, resulting in induced ele-
vation of alcohol consumption, neither
drug was specific for reducing alcohol con-
sumption in the context of stress-induced
anxiety.
In preclinical studies using similar par-
adigms for testing anxiety such as the ele-
vated plus maze, baclofen, when given in
doses comparable to those used in this
study (3.0 mg/kg), is not anxiolytic. Rather,
administration of baclofen results in a non-
specific behavioral inhibition (32). Further,
in the specific test used in this study to
measure anxiety, the light-dark box, while
baclofen has not been studied, a GABAB
receptor antagonist shows no anxiogenic
effect (33). With respect to alcohol, in
contrast, in rodent studies, baclofen (1.25
and 2.5 mg/kg) reduces measures of anx-
iety from alcohol (18, 34). In humans, it
decreases the anxiety associated with alco-
hol withdrawal, as stated above. Consider-
ing, therefore, the results of the study by
Peters and colleagues, it is possible that
the effect of baclofen was to produce a
decrease in the rewarding property of alco-
hol in both housing contexts, that is, the
drug’s effect was not specific for the anxio-
genic phenotype driving increased alcohol
consumption.
The results for oxytocin mirror those
seen in another rodent study examining
the effect of oxytocin on alcohol consump-
tion outside of a stress context (29). In
this study by McGregor and colleagues
(29) a single dose of oxytocin (a tenth of
that used in the present study: 1 mg/kg)
given i.p. reduced alcohol consumption
over 6 weeks, without a significant over-
all change in fluid intake. Notably, Peters
and colleagues administered oxytocin both
peripherally and centrally, but no effects
were seen when it was administered cen-
trally. It is difficult, however, to speculate
why central administration did not repli-
cate the same findings of when oxytocin
was given i.p. Furthermore, it is unclear
why given oxytocin’s well demonstrated
anxiolytic effect (35) there was no effect
of oxytocin on alcohol consumption post
stress-induced anxiety? Despite the anx-
iogenic phenotype produced as a conse-
quence of CSC, the CSC model has not
been shown to impact oxytocin expres-
sion, at least in the paraventricular nucleus
of the hypothalamus (36). There might,
though, be other brain regions where oxy-
tocin is upregulated, such as the suprop-
tic nucleus where dendritic release has
been shown to impact CNS oxytocin lev-
els (37). Further, in other stress mod-
els, such as social defeat, there is an up-
regulation of oxytocin receptor mRNA
in the lateral septum and medial amyg-
dala (38). If endogenous oxytocin was
modulated due to the CSC stressor, then
perhaps no effect of a single dose of
intraperitoneal or intracerebroventricular
oxytocin was apparent due to a ceiling
effect of oxytocin resulting from the stres-
sor. Further research into the neural path-
ways modulated by both oxytocin and
baclofen with respect to drinking behav-
ior in this stress model is warranted. In
summary, further characterization of this
rodent social stress model to investigate
anxiety-like behavior after both stress and
alcohol exposure would inform the use
of this model to test medications that
are themselves anxiolytic. Also, alternative
experimental designs employing this ani-
mal model might include either adminis-
tration of the medication of interest before
the stress manipulation to see if the med-
ication protects against development of
anxiety and/or increased alcohol consump-
tion, or after the social stressor but before
alcohol exposure.
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